Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 198

1.

Randomized, Phase II Study Prospectively Evaluating Treatment of Metastatic Esophageal, Gastric, or Gastroesophageal Cancer by Gene Expression of ERCC1: SWOG S1201.

Iqbal S, McDonough S, Lenz HJ, Ilson D, Burtness B, Nangia CS, Barzi A, Schneider CJ, Liu JJ, Dotan E, Guthrie KA, Hochster HS.

J Clin Oncol. 2019 Dec 9:JCO1900925. doi: 10.1200/JCO.19.00925. [Epub ahead of print]

PMID:
31815582
2.

Multi-Institutional Validation of Deep Learning for Pretreatment Identification of Extranodal Extension in Head and Neck Squamous Cell Carcinoma.

Kann BH, Hicks DF, Payabvash S, Mahajan A, Du J, Gupta V, Park HS, Yu JB, Yarbrough WG, Burtness BA, Husain ZA, Aneja S.

J Clin Oncol. 2019 Dec 9:JCO1902031. doi: 10.1200/JCO.19.02031. [Epub ahead of print]

PMID:
31815574
3.

Immunotherapy for head and neck cancer: Recent advances and future directions.

Cramer JD, Burtness B, Ferris RL.

Oral Oncol. 2019 Dec;99:104460. doi: 10.1016/j.oraloncology.2019.104460. Epub 2019 Nov 1. Review.

PMID:
31683169
4.

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.

Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D; KEYNOTE-048 Investigators.

Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1.

PMID:
31679945
5.

Impact of contralateral lymph nodal involvement and extranodal extension on survival of surgically managed HPV-positive oropharyngeal cancer staged with the AJCC eighth edition.

Miccio JA, Verma V, Kelly J, Kann BH, An Y, Park HS, Eskander A, Burtness B, Husain Z.

Oral Oncol. 2019 Dec;99:104447. doi: 10.1016/j.oraloncology.2019.104447. Epub 2019 Oct 17.

PMID:
31630059
6.

Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer.

Argiris A, Li S, Savvides P, Ohr JP, Gilbert J, Levine MA, Chakravarti A, Haigentz M Jr, Saba NF, Ikpeazu CV, Schneider CJ, Pinto HA, Forastiere AA, Burtness B.

J Clin Oncol. 2019 Dec 1;37(34):3266-3274. doi: 10.1200/JCO.19.00555. Epub 2019 Oct 16.

PMID:
31618129
7.

Clinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant Therapy.

Loganadane G, Kann BH, Park HS, Johnson SB, Mehra S, Judson BL, Bhatia A, Belkacemi Y, Yarbrough WG, Burtness B, Husain ZA.

Anticancer Res. 2019 Sep;39(9):4885-4890. doi: 10.21873/anticanres.13674.

PMID:
31519591
8.

Neuregulin Signaling Is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma.

Baro M, Lopez Sambrooks C, Burtness BA, Lemmon MA, Contessa JN.

Mol Cancer Ther. 2019 Nov;18(11):2124-2134. doi: 10.1158/1535-7163.MCT-19-0163. Epub 2019 Aug 6.

PMID:
31387891
9.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).

Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, Licitra L, Mehanna H, Mell LK, Raben A, Sikora AG, Uppaluri R, Whitworth F, Zandberg DP, Ferris RL.

J Immunother Cancer. 2019 Jul 15;7(1):184. doi: 10.1186/s40425-019-0662-5.

10.

Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial.

Burtness B, Haddad R, Dinis J, Trigo J, Yokota T, de Souza Viana L, Romanov I, Vermorken J, Bourhis J, Tahara M, Martins Segalla JG, Psyrri A, Vasilevskaya I, Nangia CS, Chaves-Conde M, Kiyota N, Homma A, Holeckova P, Del Campo JM, Asarawala N, Nicolau UR, Rauch D, Even C, Wang B, Gibson N, Ehrnrooth E, Harrington K, Cohen EEW; LUX-Head & Neck 2 investigators.

JAMA Oncol. 2019 Jun 13. doi: 10.1001/jamaoncol.2019.1146. [Epub ahead of print]

PMID:
31194247
11.

The changing therapeutic landscape of head and neck cancer.

Cramer JD, Burtness B, Le QT, Ferris RL.

Nat Rev Clin Oncol. 2019 Nov;16(11):669-683. doi: 10.1038/s41571-019-0227-z. Epub 2019 Jun 12. Review.

PMID:
31189965
12.

Gender disparities in head and neck cancer chemotherapy clinical trials participation and treatment.

Benchetrit L, Torabi SJ, Tate JP, Mehra S, Osborn HA, Young MR, Burtness B, Judson BL.

Oral Oncol. 2019 Jul;94:32-40. doi: 10.1016/j.oraloncology.2019.05.009. Epub 2019 May 14.

PMID:
31178210
13.

Point/Counterpoint: Do We De-escalate Treatment of HPV-Associated Oropharynx Cancer Now? And How?

Wirth LJ, Burtness B, Nathan CO, Grégoire V, Richmon J.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:364-372. doi: 10.1200/EDBK_238315. Epub 2019 May 17. Review.

14.

Pathologic staging changes in oral cavity squamous cell carcinoma: Stage migration and implications for adjuvant treatment.

Lee NCJ, Eskander A, Park HS, Mehra S, Burtness BA, Husain Z.

Cancer. 2019 Sep 1;125(17):2975-2983. doi: 10.1002/cncr.32161. Epub 2019 May 15.

PMID:
31090934
15.

Hyperprogression after one dose of nivolumab in sinonasal cancer: A case report.

Xiang JJ, Uy NF, Minja FJ, Verter EE, Burtness BA.

Laryngoscope. 2019 May 6. doi: 10.1002/lary.28042. [Epub ahead of print]

PMID:
31058321
16.

Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer: ASCO Provisional Clinical Opinion.

Adelstein DJ, Ismaila N, Ku JA, Burtness B, Swiecicki PL, Mell L, Beitler JJ, Gross N, Jones CU, Kaufman M, Le QT, Semrad TJ, Siu LL, Ridge JA.

J Clin Oncol. 2019 Jun 20;37(18):1578-1589. doi: 10.1200/JCO.19.00441. Epub 2019 Apr 25.

PMID:
31021656
17.

PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma.

Eze N, Lee JW, Yang DH, Zhu F, Neumeister V, Sandoval-Schaefer T, Mehra R, Ridge JA, Forastiere A, Chung CH, Burtness B.

Oral Oncol. 2019 Apr;91:69-78. doi: 10.1016/j.oraloncology.2019.02.026. Epub 2019 Mar 4.

18.

Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling.

Khan SA, Ci B, Xie Y, Gerber DE, Beg MS, Sherman SI, Cabanillas ME, Busaidy NL, Burtness BA, Heilmann AM, Bailey M, Ross JS, Sher DJ, Ali SM.

Head Neck. 2019 Jun;41(6):1928-1934. doi: 10.1002/hed.25634. Epub 2019 Feb 13.

PMID:
30758123
19.

Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck.

Lee JW, Parameswaran J, Sandoval-Schaefer T, Eoh KJ, Yang DH, Zhu F, Mehra R, Sharma R, Gaffney SG, Perry EB, Townsend JP, Serebriiskii IG, Golemis EA, Issaeva N, Yarbrough WG, Koo JS, Burtness B.

Clin Cancer Res. 2019 Jun 1;25(11):3430-3442. doi: 10.1158/1078-0432.CCR-18-0440. Epub 2019 Feb 12.

20.

Radiation therapy treatment facility and overall survival in the adjuvant setting for locally advanced head and neck squamous cell carcinoma.

Lee NCJ, Kelly JR, An Y, Park HS, Judson BL, Burtness BA, Husain ZA.

Cancer. 2019 Jun 15;125(12):2018-2026. doi: 10.1002/cncr.32001. Epub 2019 Feb 12.

PMID:
30748002
21.

APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma.

Cannataro VL, Gaffney SG, Sasaki T, Issaeva N, Grewal NKS, Grandis JR, Yarbrough WG, Burtness B, Anderson KS, Townsend JP.

Oncogene. 2019 May;38(18):3475-3487. doi: 10.1038/s41388-018-0657-6. Epub 2019 Jan 15.

22.

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.

Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ; KEYNOTE-040 investigators.

Lancet. 2019 Jan 12;393(10167):156-167. doi: 10.1016/S0140-6736(18)31999-8. Epub 2018 Nov 30. Erratum in: Lancet. 2019 Jan 12;393(10167):132.

PMID:
30509740
23.

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.

Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, Sturgis EM, Burtness B, Ridge JA, Ringash J, Galvin J, Yao M, Koyfman SA, Blakaj DM, Razaq MA, Colevas AD, Beitler JJ, Jones CU, Dunlap NE, Seaward SA, Spencer S, Galloway TJ, Phan J, Dignam JJ, Le QT.

Lancet. 2019 Jan 5;393(10166):40-50. doi: 10.1016/S0140-6736(18)32779-X. Epub 2018 Nov 15.

24.

Pretreatment Identification of Head and Neck Cancer Nodal Metastasis and Extranodal Extension Using Deep Learning Neural Networks.

Kann BH, Aneja S, Loganadane GV, Kelly JR, Smith SM, Decker RH, Yu JB, Park HS, Yarbrough WG, Malhotra A, Burtness BA, Husain ZA.

Sci Rep. 2018 Sep 19;8(1):14036. doi: 10.1038/s41598-018-32441-y.

25.

Patterns of failure in high-metastatic node number human papillomavirus-positive oropharyngeal carcinoma.

Lee NCJ, Kelly JR, Park HS, An Y, Judson BL, Burtness BA, Husain ZA.

Oral Oncol. 2018 Oct;85:35-39. doi: 10.1016/j.oraloncology.2018.08.001. Epub 2018 Aug 20.

PMID:
30220317
26.

HPV status in unknown primary head and neck cancer: Prognosis and treatment outcomes.

Cheraghlou S, Torabi SJ, Husain ZA, Otremba MD, Osborn HA, Mehra S, Yarbrough WG, Burtness BA, Judson BL.

Laryngoscope. 2019 Mar;129(3):684-691. doi: 10.1002/lary.27475. Epub 2018 Aug 27.

PMID:
30151832
27.

Treatment Delays in Primarily Resected Oropharyngeal Squamous Cell Carcinoma: National Benchmarks and Survival Associations.

Morse E, Judson B, Husain Z, Burtness B, Yarbrough WG, Sasaki C, Cheraghlou S, Mehra S.

Otolaryngol Head Neck Surg. 2018 Jul 31:194599818779052. doi: 10.1177/0194599818779052. [Epub ahead of print]

PMID:
30060700
28.

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012.

Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Geva R, Chung HC, Lin CC, Aurora-Garg D, Ray A, Pathiraja K, Cheng J, Chow LQM, Haddad R.

Br J Cancer. 2018 Jul;119(2):153-159. doi: 10.1038/s41416-018-0131-9. Epub 2018 Jun 29.

29.

National treatment times in oropharyngeal cancer treated with primary radiation or chemoradiation.

Morse E, Judson B, Husain Z, Burtness B, Yarbrough W, Sasaki C, Cheraghlou S, Mehra S.

Oral Oncol. 2018 Jul;82:122-130. doi: 10.1016/j.oraloncology.2018.02.010. Epub 2018 May 26.

PMID:
29909886
30.

Adjuvant therapy in major salivary gland cancers: Analysis of 8580 patients in the National Cancer Database.

Cheraghlou S, Kuo P, Mehra S, Agogo GO, Bhatia A, Husain ZA, Yarbrough WG, Burtness BA, Judson BL.

Head Neck. 2018 Jul;40(7):1343-1355. doi: 10.1002/hed.24984. Epub 2018 May 13.

PMID:
29756412
31.

NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018.

Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Eisele DW, Fenton M, Foote RL, Gilbert J, Gillison ML, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Zhen W, Burns JL, Darlow SD.

J Natl Compr Canc Netw. 2018 May;16(5):479-490. doi: 10.6004/jnccn.2018.0026.

32.

Upfront surgery versus definitive chemoradiotherapy in patients with human Papillomavirus-associated oropharyngeal squamous cell cancer.

Kelly JR, Park HS, An Y, Yarbrough WG, Contessa JN, Decker R, Mehra S, Judson BL, Burtness B, Husain Z.

Oral Oncol. 2018 Apr;79:64-70. doi: 10.1016/j.oraloncology.2018.02.017. Epub 2018 Mar 8.

PMID:
29598952
33.

Postoperative Chemoradiation in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck.

Bhatia AK, Burtness BA, Decker RH.

J Clin Oncol. 2018 May 1;36(13):1269-1271. doi: 10.1200/JCO.2018.77.7987. Epub 2018 Mar 16. No abstract available.

PMID:
29547345
34.

NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis.

Peri S, Izumchenko E, Schubert AD, Slifker MJ, Ruth K, Serebriiskii IG, Guo T, Burtness BA, Mehra R, Ross EA, Sidransky D, Golemis EA.

Nat Commun. 2017 Nov 24;8(1):1772. doi: 10.1038/s41467-017-01877-7.

35.

Response.

Bledsoe TJ, Park HS, Stahl JM, Yarbrough WG, Burtness BA, Decker RH, Husain ZA.

J Natl Cancer Inst. 2018 Apr 1;110(4):433-434. doi: 10.1093/jnci/djx230. No abstract available.

PMID:
29121329
36.

The tumor genome in human immunodeficiency virus-related head and neck cancer: Exploitable targets?

Burtness B.

Cancer. 2018 Jan 1;124(1):14-17. doi: 10.1002/cncr.31059. Epub 2017 Oct 20. No abstract available.

37.

Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.

Cohen EEW, Licitra LF, Burtness B, Fayette J, Gauler T, Clement PM, Grau JJ, Del Campo JM, Mailliez A, Haddad RI, Vermorken JB, Tahara M, Guigay J, Geoffrois L, Merlano MC, Dupuis N, Krämer N, Cong XJ, Gibson N, Solca F, Ehrnrooth E, Machiels JH.

Ann Oncol. 2017 Oct 1;28(10):2526-2532. doi: 10.1093/annonc/mdx344.

38.

Demethylation Therapy as a Targeted Treatment for Human Papillomavirus-Associated Head and Neck Cancer.

Biktasova A, Hajek M, Sewell A, Gary C, Bellinger G, Deshpande HA, Bhatia A, Burtness B, Judson B, Mehra S, Yarbrough WG, Issaeva N.

Clin Cancer Res. 2017 Dec 1;23(23):7276-7287. doi: 10.1158/1078-0432.CCR-17-1438. Epub 2017 Sep 15.

39.

Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck.

Bhatia A, Burtness B.

Cancers (Basel). 2017 Aug 31;9(9). pii: E113. doi: 10.3390/cancers9090113. Review.

40.

Biomarker driven treatment of head and neck squamous cell cancer.

Eze N, Lo YC, Burtness B.

Cancers Head Neck. 2017 Aug 29;2:6. doi: 10.1186/s41199-017-0025-1. eCollection 2017. Review.

41.

Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590).

Bhatia AK, Lee JW, Pinto HA, Jacobs CD, Limburg PJ, Rubin P, Arusell RM, Dunphy EP, Khandekar JD, Reiner SA, Baez-Diaz L, Celano P, Li S, Li Y, Burtness BA, Adams GL, Pandya KJ.

Cancer. 2017 Dec 1;123(23):4653-4662. doi: 10.1002/cncr.30920. Epub 2017 Aug 7.

42.

Immune Checkpoint Inhibition in Cancers that Affect the Head and Neck.

Parameswaran J, Burtness B.

Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):969-973. doi: 10.1016/j.ijrobp.2017.03.003. Epub 2017 Jul 10. No abstract available.

PMID:
28721906
43.

Lymph-node-positive cutaneous nonmelanoma skin cancer: A poor-prognosis disease in need of treatment intensification.

Wang LS, Handorf EA, Ridge JA, Burtness BA, Lango MN, Mehra R, Liu JC, Galloway TJ.

Ear Nose Throat J. 2017 Jul;96(7):E12-E18.

PMID:
28719713
44.

Treatment guidelines and patterns of care in oral cavity squamous cell carcinoma: Primary surgical resection vs. nonsurgical treatment.

Fujiwara RJT, Burtness B, Husain ZA, Judson BL, Bhatia A, Sasaki CT, Yarbrough WG, Mehra S.

Oral Oncol. 2017 Aug;71:129-137. doi: 10.1016/j.oraloncology.2017.06.013. Epub 2017 Jun 23.

PMID:
28688680
45.

NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017.

Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Gilbert J, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Lydiatt WM, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD.

J Natl Compr Canc Netw. 2017 Jun;15(6):761-770. doi: 10.6004/jnccn.2017.0101.

46.

Hypofractionated Radiotherapy for Patients with Early-Stage Glottic Cancer: Patterns of Care and Survival.

Bledsoe TJ, Park HS, Stahl JM, Yarbrough WG, Burtness BA, Decker RH, Husain ZA.

J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx042.

PMID:
28521361
47.

Reply to A. Garden et al.

Marur S, Li S, Cmelak A, Burtness B.

J Clin Oncol. 2017 Jun 10;35(17):1970-1971. doi: 10.1200/JCO.2017.72.8279. Epub 2017 Apr 21. No abstract available.

PMID:
28430530
48.

Purpose of Induction Chemotherapy in E1308 and Importance of Patient-Reported Outcomes in Deintensification Trials.

Marur S, Cmelak AJ, Burtness B.

J Clin Oncol. 2017 Jun 10;35(17):1968-1969. doi: 10.1200/JCO.2017.72.2918. Epub 2017 Apr 21. No abstract available.

PMID:
28430529
49.

The risk of level IB nodal involvement in oropharynx cancer: Guidance for submandibular gland sparing irradiation.

Lee NCJ, Kelly JR, Park HS, Yarbrough WG, Burtness BA, Husain ZA.

Pract Radiat Oncol. 2017 Sep - Oct;7(5):e317-e321. doi: 10.1016/j.prro.2017.02.004. Epub 2017 Feb 16.

PMID:
28356201
50.

The prognostic value of extranodal extension in human papillomavirus-associated oropharyngeal squamous cell carcinoma.

An Y, Park HS, Kelly JR, Stahl JM, Yarbrough WG, Burtness BA, Contessa JN, Decker RH, Koshy M, Husain ZA.

Cancer. 2017 Jul 15;123(14):2762-2772. doi: 10.1002/cncr.30598. Epub 2017 Mar 21.

Supplemental Content

Loading ...
Support Center